DHD
Dược Vật tư Y tế Hải Dương ·UPCOM ·2026Q1
▲▲ Improving positively
TTM · Applied to: EPS, ROE, ROA, Net Margin, Asset Turnover, Debt/Equity
What Is Changing
On a TTM 2026Q1 basis, DHD is improving on both growth and profitability, painting a notably more positive picture versus the same period — profit is at an all-time high. When both scale and efficiency improve together, this is typically a sign of quality growth.
| Metric | Q1'26 | Q4'25 | Q3'25 | Q2'25 | Q1'25 | Q4'24 | Q3'24 | Q2'24 | Q1'24 | Q4'23 | Q3'23 | Q2'23 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 192.2 | 196.1 | 164.6 | 162.1 | 160.9 | 183.5 | 160.6 | 174.2 | 146.6 | 165.8 | 139.0 | 128.5 |
| Growth | -2% | +19% | +2% | +1% | -12% | +14% | -8% | +19% | -12% | +19% | +8% | — |
| Net Income | 16.9 | 17.6 | 13.0 | 11.9 | 13.3 | 11.8 | 10.5 | 10.1 | 8.1 | 7.8 | 8.2 | 7.1 |
| Net Margin | 8.79% | 8.95% | 7.88% | 7.32% | 8.27% | 6.45% | 6.57% | 5.77% | 5.54% | 4.68% | 5.89% | 5.50% |
Drivers of DHD's profit
Net profit attributable to parent increased vs last year, mainly helped by higher gross profit. Supporting and offsetting drivers:
Net profit attributable to parent increased vs prior quarter, mainly helped by higher gross profit. Supporting and offsetting drivers:
Financial Highlights
Detailed analysis of each financial dimension
ROE = Profit Margin × Asset Turnover × Equity Multiplier
ROE rose from 10.2% to 12.0% — mainly driven by leverage, despite asset turnover moving in the opposite direction.
Is the profit sustainable?
Margins are improving and earnings quality is solid — a durable foundation for ROE.
What is driving the margin?
Net margin expanded to 8.29%, rising 1.6pp. Core operating signals are improving as Gross margin rose 2.2pp are enough to offset pressure from SG&A / Revenue rose 0.3pp (in addition, Net financial result / Revenue rose 0.1pp added support while Other profit / Revenue fell 0.1pp remained a drag).
The improvement comes from core operations — this is a high-quality margin expansion.
Profitability trend
TTM YoY · 2025Q1 -> 2026Q1
Is capital being used efficiently?
Evaluate capital, asset, and working-capital efficiency.
Is capital being deployed efficiently?
ROIC stands at 8.87%, broadly flat versus the same period. That translates to 8.87 in after-tax operating profit for every 100 units of operating capital. NOPAT margin rose 1.6pp, but capital turnover fell 0.27x, while invested capital expanded strongly by 156bn — the two factors are offsetting each other, keeping overall ROIC nearly unchanged.
Overall ROIC is flat while internal components are moving — watch which side becomes dominant in coming periods.
CAPITAL EFFICIENCY TREND
TTM YoY · 2025Q1 -> 2026Q1
Balance Sheet
Capital structure is conservative with low leverage — liabilities at 0.89x equity, net debt at 0.49x equity.
Inventory ended the period at 143.6bn, roughly 15.1% of total assets.
Over the last 12 months, working capital absorbed 8.1bn of cash, mainly because of higher inventories and lower payables. Part of that drag was offset by lower receivables.
Working Capital Drivers
TTM YoY · 2025Q1 -> 2026Q1
Working Capital Efficiency
Cash conversion cycle lengthened by 3.8 days versus the same period last year. The main moves came from DIO rose 14.5 days, DSO rose 2.7 days, and DPO rose 13.5 days.
Working capital cycle lengthened mainly due to slower inventory turnover — more capital is being tied up in inventory.
Watchpoints
CCC stands at 117.5 days, suggesting that working capital remains tied up for a relatively long operating cycle.
DSO increased by +2.7 days, pointing to slower receivables turnover.
Working Capital Efficiency
TTM YoY · 2025Q1 -> 2026Q1
Is financial risk significant?
Leverage is safe but FCF is negative at 183.9bn due to capex of 265.2bn — an investment choice, not an urgent risk.
Leverage & Liquidity
Leverage looks fairly comfortable, with net debt / equity at 0.49x and interest coverage at 12.28x.
At present, short-term debt accounts for 22.9% of total debt, cash equals 16.5% of debt, and total debt stands at 307.3bn.
Watchpoints
Cash / debt stands at 16.5%, leaving limited liquidity buffer to monitor.
Leverage and liquidity trend
TTM YoY · 2025Q1 -> 2026Q1
Cash Flow
With safe leverage noted above, cash flow below shows the self-funding capacity. Operating cash flow reached 55.7bn in 2025, against investing cash flow of -268.3bn.
Post-investment cash flow was negative +212.6bn. Financing cash flow was positive +225.8bn.
CFO / net income was 1.37x.
After spending +265.2bn on fixed-asset investment, the business generated trailing free cash flow of −183.9bn.
Cash Conversion
TTM Cash Conversion · 2025Q1 -> 2026Q1
Investment Takeaway
The business is heading the right way, but the current picture is still at partial confirmation — not yet a fully clean case. The positive points have clearly improved, showing the operating base is better than before. The brighter spot is operating efficiency, with net margin improving 1.6 pp. The main risk still sits in self-funded cash generation remains weak.
Improvement: operating efficiency is getting better, with trailing-12M net margin at 8.29% after expanding 1.6pp versus the same period last year.
Key risk: self-funded cash generation remains weak, with trailing-12M FCF still at 183.9bn.
Statement Data
| Item | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|
|
Net Revenue
|
683.7 | 665.0 | 614.7 | 615.8 |
|
Cost of Goods Sold
|
438.7 | 454.8 | 426.7 | 442.9 |
|
Gross Profit
|
245.0 | 210.2 | 188.1 | 172.9 |
|
Financial Expenses
|
5.7 | 6.3 | 8.5 | 6.5 |
|
Selling Expenses
|
79.0 | 74.1 | 68.6 | 61.0 |
|
General and Administrative Expenses
|
93.2 | 81.8 | 72.7 | 69.1 |
|
Operating Profit
|
68.3 | 48.6 | 38.6 | 36.5 |
|
Profit Before Tax
|
69.8 | 50.8 | 39.5 | 37.8 |
|
Net Income
|
55.7 | 40.6 | 31.5 | 30.0 |
|
Profit Attributable to Parent
|
55.7 | 40.6 | 31.5 | 30.0 |
|
Earnings per Share
|
1,548.00 | 1,453.00 | 1,545.00 | 2,255.00 |
Explore Other Stocks In The Same Sector
DHG, DVN, IMP, DBD, DTP, TRA, DMC, DP3, OPC, NDC, DAN, PMC, VDP, DHT, FIT, AGP, DVM, CNC, PBC, LDP, DPH, VMD, NDP, HDP, DCL, PPP, VET, MTP, MKV, DHN, MED, DBT, DTG, DPP, BIO, VNY, DBM, MKP, TW3, DTH, NTF, BCP, UPH, SPM, DP2, VXP
Need support? If you need support with content lookup or want to provide feedback about content on the website, please contact us below.